Irina Grigorescu[email protected]Prostate CancerHow deep learning can help predict cancer recurrenceProstate cancer is the second most common cancer affecting men worldwide, with an incidence rate of 13.5%, according to the World Health Organization. Expert pathologists diagnose this type of cancer through a transrectal biopsy, following the results of a prostate-specific antigen (PSA) test. The extracted samples of tissue are examined under a microscope and, if cancerous cells are found, divided into risk groups assigned through the Gleason score. This grading system is considered the gold standard in cancer medicine, as it determines the aggressiveness of prostate cancer and helps doctors establish the right course of treatment.February 16, 2020Page 1 of 1Top StoriesLawsuitLegal team highlights cautionary clinical laboratory fraud caseClinical laboratory litigation indicates growing trend of cases filed by nontraditional whistleblowers.Emerging TechnologyWhat's coming in clinical genomics?Policy and RegulationLab leaders advised to maintain communication with regulatory agencies during blackoutLawsuitFederal judge dismisses pathology group antitrust caseSponsor ContentBody composition in patients treated with Ozempic